Enveric Biosciences, Inc. (ENVB)

NASDAQ: ENVB · IEX Real-Time Price · USD
0.182
-0.018 (-9.05%)
At close: Jun 24, 2022 4:00 PM
0.190
+0.008 (4.396%)
After-hours: Jun 24, 2022 7:57 PM EDT
-9.05%
Market Cap 9.59M
Revenue (ttm) n/a
Net Income (ttm) -50.25M
Shares Out 52.68M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,379,105
Open 0.200
Previous Close 0.200
Day's Range 0.182 - 0.220
52-Week Range 0.170 - 3.740
Beta 5.73
Analysts Buy
Price Target 0.66 (+262.6%)
Earnings Date Aug 12, 2022

About ENVB

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida. [Read more...]

Industry Biotechnology
Founded 1994
CEO Brent Kelton
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ENVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is 0.66, which is an increase of 262.64% from the latest price.

Price Target
$0.66
(262.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Enveric Biosciences to Participate in Upcoming Conferences in June 2022

NAPLES, Fla. , June 8, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-ins...

Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022

NAPLES, FLA , May 24, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-insp...

Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

NAPLES, Fla. , May 17, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-ins...

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treat...

Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET

NAPLES, FL , May 5, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspir...

Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

NAPLES, Fla. , May 3, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspi...

Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022

NAPLES, Fla. , April 6, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-in...

Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update

NAPLES, Fla. , March 31, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-in...

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

NAPLES, Fla., March 29, 2022 /PRNewswire/ -  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health medic...

Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates

Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders              NAPLES, Fla., March 15, 2022 /PRNewswire/ - Enveric...

Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022

NAPLES, Fla. , March 3, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental h...

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

NAPLES, Fla., March 1, 2022 /PRNewswire/ --  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspi...

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Re...

Clinical trial aim is to include the identification and characterization of the Cancer Related Distress symptoms most responsive to psychedelic-associated therapy NAPLES, Fla., Feb. 17, 2022 /PRNewswire...

Enveric Biosciences Closes $10 Million Public Offering

Psychedelics-based company Enveric Biosciences (NASDAQ:ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 m...

Enveric Biosciences Announces Closing of $10 Million Public Offering

NAPLES, Fla. , Feb. 15, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health and onc...

Enveric Biosciences Shares Fall After $10M Equity Raise

Enveric Biosciences Inc (NASDAQ: ENVB) has priced its previously announced underwritten public offering of 20 million shares and warrants to purchase up to 20 million shares at a combined price of $0.50...

Enveric Biosciences Announces Pricing of $10 Million Public Offering

NAPLES, Fla. , Feb. 11, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health and onc...

Enveric Biosciences Files Provisional Patent For CBD+Celecoxib Conjugate For Osteoarthritis

Psychedelics-based neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis and other pain indications. EV104a ...

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecox...

Target Indications include Osteoarthritis and Other Pain Conditions NAPLES, Fla. , Feb. 8, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company dev...

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

NAPLES, Fla. , Jan. 27, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology...

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

NAPLES, Fla. , Jan. 18, 2022 /PRNewswire/ -   Enveric Biosciences   (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter to shareholders from Dr....

Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

NAPLES, Fla., Jan. 6, 2022 /PRNewswire/ - Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology ...

Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer

NAPLES, Fla., Dec. 6, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology ...

Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

NAPLES, Fla., Nov. 29, 2021 /PRNewswire/ - Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology...

Enveric Biosciences' CBD-Based Product Reduces Dermatitis Severity In Animal Study

Enveric Biosciences (NASDAQ: ENVB) announced data from a preclinical rodent model evaluating EV102, the company's cannabidiol (CBD) based product in development for the topical treatment of radiodermati...